Bruno Eleonora, Manoukian Siranoush, Venturelli Elisabetta, Oliverio Andreina, Rovera Francesca, Iula Giovanna, Morelli Daniele, Peissel Bernard, Azzolini Jacopo, Roveda Eliana, Pasanisi Patrizia
1 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
2 University of Milan, Milan, Italy.
Integr Cancer Ther. 2018 Mar;17(1):153-160. doi: 10.1177/1534735417721015. Epub 2017 Jul 25.
Insulin resistance is associated with higher breast cancer (BC) penetrance in BRCA mutation carriers. Metabolic syndrome (MetS), an insulin resistance syndrome, can be reversed by adhering to the Mediterranean diet (MedDiet). In a dietary intervention trial on BRCA mutation carriers, we evaluated adherence to the MedDiet, and the association with the MetS, by analyzing data from the Mediterranean Diet Adherence Screener (MEDAS).
BRCA mutation carriers, with or without BC, aged 18 to 70 years, were eligible for the trial. After the baseline examinations, women were randomized to a dietary intervention or to a control group. Both groups completed the MEDAS at baseline and at the end of the dietary intervention.
A total of 163 women completed the 6 months of dietary intervention. Compared with controls, the women in the intervention group significantly reduced their consumption of red meat ( P < .01) and commercial sweets ( P < .01) and their MEDAS score rose significantly (+1.3 vs +0.55, P = .02). The number of MetS parameters decreased with increasing points of adherence to the MEDAS score ( P = .01). In the intervention group, there was a significant association with the greater reduction of MetS.
BRCA mutation carriers in the intervention group experienced greater improvement in their MedDiet and MetS parameters.
胰岛素抵抗与BRCA突变携带者中较高的乳腺癌(BC)发病率相关。代谢综合征(MetS)作为一种胰岛素抵抗综合征,可通过坚持地中海饮食(MedDiet)得到改善。在一项针对BRCA突变携带者的饮食干预试验中,我们通过分析地中海饮食依从性筛查工具(MEDAS)的数据,评估了对MedDiet的依从性及其与MetS的关联。
年龄在18至70岁之间、患有或未患BC的BRCA突变携带者符合该试验条件。在基线检查后,将女性随机分为饮食干预组或对照组。两组在基线时和饮食干预结束时均完成了MEDAS评估。
共有163名女性完成了6个月的饮食干预。与对照组相比,干预组女性显著减少了红肉(P <.01)和商业甜食(P <.01)的摄入量,且她们的MEDAS评分显著提高(+1.3对+0.55,P =.02)。随着MEDAS评分依从性得分的增加,MetS参数的数量减少(P =.01)。在干预组中,MetS的更大改善存在显著关联。
干预组中的BRCA突变携带者在MedDiet和MetS参数方面有更大改善。